XPO1 and cancer: Although rare, XPO1 mutations have also been observed in solid tumors, including NSCLC: in a pan-cancer survey, approximately 2.8% of NSCLC cases exhibited XPO1 alterations (copy number cthanges or mutations) [17], and in a large NSCLC cohort, 26 tumors carried XPO1 mutations and 24 showed amplifications [18].